NeuroSigma is at the forefront of developing trigeminal nerve stimulation (TNS) as a novel neuromodulation therapy aimed at treating various neurological and neuropsychiatric disorders. This technology, which was originally invented at the University of California, Los Angeles (UCLA), allows NeuroSigma to leverage exclusive worldwide rights to the associated intellectual property. The company’s research is backed by over a decade of scientific and clinical studies, demonstrating the efficacy of TNS in treating conditions such as epilepsy, depression, attention deficit hyperactivity disorder (ADHD), post-traumatic stress disorder (PTSD), Lennox-Gastaut Syndrome (LGS), and traumatic brain injury (TBI). 

One of NeuroSigma's key products is the Monarch eTNS® System, which has received FDA clearance as the first device specifically designed for the treatment of pediatric ADHD in children aged 7 to 12 who are not on prescription medications. This device is intended for home use under caregiver supervision during sleep, highlighting its non-invasive nature. While the Monarch eTNS System has been associated with mild side effects such as drowsiness and increased appetite, it has not been linked to any serious adverse events, underscoring its safety profile. NeuroSigma is dedicated to expanding access to this innovative therapy, as evidenced by its recent initiatives, including the establishment of a subsidiary in Singapore and the introduction of a telehealth option for patients and caregivers.

United States

NeuroSigma, Inc. is a Los Angeles-based bioelectronics company commercializing external trigeminal nerve stimulation (eTNS) technology.

NeuroSigma's Monarch eTNS® System is a bioelectronic medical device that uses external trigeminal nerve stimulation to treat neurological and neuropsychiatric disorders. In 2019, the Monarch eTNS System became the first-ever medical device cleared by FDA for treating pediatric ADHD.

The new Monarch Pediatric Care Co-Pay Program is making eTNS therapy available to a substantially greater number of children diagnosed with ADHD.

NeuroSigma

Company Details